

**Urologix, Inc.**  
14405 21<sup>st</sup> Ave N.  
Minneapolis, MN 55447  
763-475-1400

**Lisa Ackermann**  
VP, Sales and Marketing  
Urologix, Inc.



## **FACT SHEET**

Urologix, Inc., based in Minneapolis, Minnesota, develops, manufactures and markets minimally invasive medical products for the treatment of benign prostatic hyperplasia (BPH). The Company has developed and offers non-surgical, catheter-based treatments for BPH, a condition that affects more than 23 million men worldwide, with 9 million symptomatic BPH patients diagnosed in the United States. We are committed to innovation and advancement in the understanding and treatment of this disease.

### **Products**

Urologix' Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort while providing safe, effective, lasting relief of the symptoms and obstruction due to BPH. Urologix' Cooled ThermoTherapy products include the CoolWave® and Targis® Control Units and the CTC Advance®, Targis® and Prostateprobe® catheter families.

Urologix is the distributor of the Prostiva RF product line. The Prostiva RF Therapy System delivers radio frequency energy directly into the prostate destroying prostate tissue, which reduces constriction of the urethra, thereby relieving BPH voiding symptoms.

With the therapies combined, over 350,000 procedures have been performed in the last 10 years and the therapy is supported by multiple peer reviewed published articles demonstrating safety and efficacy through 5 years of follow-up.<sup>1, 2</sup>

Urologix' goal is to provide the urologist community with best-in-class technology solutions for in-office treatment of obstructive and symptomatic BPH, augmented by world class service. With the inclusion of the Prostiva RF Therapy System into our available treatment options,

---

<sup>1</sup> Hill, B., et. al., Transurethral Needle Ablation vs TURP for the treatment of Symptomatic BPH: 5-Year Results of a Prospective, Randomized, Multicenter Clinical Trial, *Journal of Urology* Vol 171, 2336-2340, June 2004

<sup>2</sup> Mynderse, L., et. al., Results of a Multi-Center Trial of a New Generation Cooled ThermoTherapy for BPH, *Journal of Urology*, May 2010, Vol 185, No 5

Urologix believes it now offers the best solution set for the treatment of bladder outlet obstruction due to BPH for the widest range of patient indications.

## Milestones

- 1991 Urologix is founded to develop, manufacture and market medical devices for the treatment of urological disorders.
- 1997 Urologix' first product, the Targis System, is approved by the FDA as a safe, durable, minimally invasive treatment alternative to drugs and surgery for the treatment of BPH.
- 2000 Urologix purchases the Prostatron<sup>®</sup> System from EDAP TMS.
- 2002 Targis Short Microwave Catheter is introduced for more precise therapy to shorter prostatic urethral lengths. Cooled ThermoCath<sup>®</sup> Microwave Catheter (CTC) receives FDA approval.
- 2005 Urologix acquires three regional mobile BPH treatment service providers and launches Urologix Mobile<sup>™</sup> service in five select U.S. regions.
- 2006 Urologix expands Urologix Mobile nationwide, providing additional service options for urologists to deliver efficient and effective BPH treatment to their patients.
- 2006 The new CoolWave Control Unit, which enables urologists to better customize BPH treatments for individual patients, is approved by the FDA and launched.
- 2008 CTC Advance family of catheters launched to further enhance patient comfort.
- 2009 Urologix presents two Moderated Posters at the 2009 AUA Annual Meeting: *5 Year Results of a Multi-Center Trial of a New Generation Cooled TUMT for BPH* and *Effects of Urethral Temperature on Patient Outcome for BPH with Cooled High Energy TUMT*.
- 2011 Urologix' durability study, *5 Year Results of a Multi-center Trial of a New Generation Cooled High Energy Transurethral Microwave Thermal Therapy Catheter for Benign Prostatic Hyperplasia*, is published in the May issue of The Journal of Urology.
- 2011 Urologix signs an Exclusive Worldwide License for the Prostiva RF Therapy System for BPH from Medtronic, Inc.

Urologix' stock is traded on NASDAQ under the symbol ULGX.

**For more information**, visit the [www.urologix.com](http://www.urologix.com)  
or call Urologix' toll-free number (888-229-0772).

###

Cooled ThermoTherapy<sup>™</sup> is available by prescription only. This therapy is not for everyone. Talk to your physician to see if Cooled ThermoTherapy is right for you. Most medical procedures may have side effects. Possible side effects for Cooled ThermoTherapy include blood in urine, clots in urine, painful or difficult urination, thickened bladder muscle, rectal irritation, temporary inability to control urination, brief inability to achieve or maintain an erection and the inability to discharge semen in orgasm thus should be considered by men who wish to have further offspring. A small risk of urethral stricture may result requiring further intervention. Patients may experience discomfort during the procedure that may require the use of analgesics or sedatives. Patients may be catheterized for a 2 to 5 day period following the treatment.<sup>1</sup> For more complete information about the benefits and risks associated with Cooled ThermoTherapy please refer to the Instructions for Use found on our website at [www.cooledthermotherapy.com](http://www.cooledthermotherapy.com) or call us at 1.800.475.1403.

<sup>1</sup>Data taken from the CTC Advance<sup>®</sup> Instructions for Use, 250348 Rev B 12/08.

Cooled ThermoTherapy is a trademark of Urologix, Inc. ©2011 Urologix, Inc. All rights reserved.